Last reviewed · How we verify
OrienX010
At a glance
| Generic name | OrienX010 |
|---|---|
| Also known as | Recombinant Human GM-CSF Herpes Simplex Virus Injection |
| Sponsor | OrienGene Biotechnology Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma (PHASE1)
- A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients (PHASE2)
- Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma (PHASE1)
- A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c
- A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OrienX010 CI brief — competitive landscape report
- OrienX010 updates RSS · CI watch RSS
- OrienGene Biotechnology Ltd. portfolio CI